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Physiol Genomics 46: 411– 417, 2014. First published May 1,
2014; doi:10.1152/physiolgenomics.00178.2013.—The nuclear factor
(erythroid-derived 2)-like 2 (NFE2L2 or NRF2) gene regulates tran-
scription of enzymes involved in cellular detoxification and lipids
homeostasis. NFE2L2 is associated with pathophysiology of athero-
sclerosis and chronic obstructive pulmonary disease (COPD). There-
fore we studied the relation between NFE2L2 and all-cause, cardio-
vascular, and COPD mortality and its associations with triglyceride
and cholesterol levels. We genotyped five tagging single nucleotide
polymorphisms (SNPs) (rs4243387, rs2364723, rs13001694,
rs1806649, and rs6726395) in NFE2L2 in 1,390 subjects from the
Vlagtwedde-Vlaardingen cohort. Participants were examined in 1989/
1990 and followed up till the vital status evaluation on December 31st,
2008. Associations between SNPs and mortality were estimated by
Cox proportional hazards regression, and associations between SNPs
and triglyceride and cholesterol levels were tested with linear regres-
sion. After 18 yr, 284 (20.4%) subjects had died, 107 from cardio-
vascular disease and 20 from COPD. Minor allele carriers of
rs13001694 had a significantly reduced risk of all-cause mortality
compared with wild types: hazard ratio (HR) 0.8 [95% confidence
interval (CI) 0.6 to 1.0]. Minor allele carriers of rs2364723 had
significantly reduced risk of cardiovascular mortality: HR  0.5 (95%
CI: 0.3–0.7). This result was consistent in stratified analyses: females
0.4 (0.2–0.7), males 0.6 (0.3–0.9), never smokers 0.5 (0.2–1.1), ever
smokers 0.5 (0.3–0.8). Minor allele carriers of rs1806649 had a
markedly reduced COPD mortality: HR  0.3 (95% CI: 0.1–0.9).
Rs2364723 was associated with lower triglyceride levels. None of the
SNPs was associated with cholesterol levels. This study shows for the
first time that NFE2L2 is associated with reduced risk of all-cause,
cardiovascular and COPD mortality in humans.
NFE2L2; all-cause mortality; general population; cardiovascular mor-
tality; COPD mortality
NEARLY 30% OF THE INDIVIDUAL variance in life expectancy is
genetically determined (6); however, the specific genetic de-
terminants of the human lifespan still remain largely unknown.
A candidate gene for predicting variation in human lifespan is
the nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or
NRF2) gene. NFE2L2 is a master regulator of antioxidant-
related genes and genes that control immune and inflammatory
responses and those involved in tissue remodeling (9) and thus
has an important role in cytoprotection in the whole organism.
NFE2L2 is a basic leucine zipper transcription factor and
regulates expression of genes, via direct binding to the antiox-
idant responsive element in the target gene. The targets include
genes encoding glutathione S-transferases, -glutamylcysteine
ligases, heme oxygenase 1, and NADPH quinione oxidoreduc-
tase (4, 14). NFE2L2 is expressed in all tissues, with highest
levels in the key detoxification organs being the kidney and
liver (11). Despite the well-documented relationship between
NFE2L2 and cellular protective mechanisms relevant to aging,
very few studies have evaluated the role of NFE2L2 in medi-
ating rates of aging and longevity (10, 17, 22, 26). One of these
studies indicated that NFE2L2 may be important in longevity,
since this gene was sixfold overexpressed in the liver of the
naked mole rat, a species with a very long lifespan compared
with mice, which have much shorter lifespans (26). In human
fibroblasts it has been demonstrated that NFE2L2 function
declines in senescence, whereas silencing of NFE2L2 leads to
premature senescence (10). Furthermore, the broad role of
NFE2L2 in age-related diseases has been indicated by its
association with the development of atherosclerosis (1, 5, 18,
27) and chronic obstructive pulmonary disease (COPD) (12,
15). Atherosclerosis is characterized by lipid deposition in the
artery wall, and the impact of NFE2L2 on atherosclerosis
development may be mediated by its role in lipid homeostasis
(8). The previous studies, performed in mice, have shown that
the expression of NFE2L2 regulates the expression of lipogenic
genes and affects lipid accumulation and deposition in aortic
lesions (1).
The Vlagtwedde-Vlaardingen cohort offers a unique oppor-
tunity to investigate the role of NFE2L2 in long-term survival,
since subjects included in this study were followed for 18 yr.
Besides all-cause mortality, we evaluated the association be-
tween NFE2L2 and cardiovascular and COPD mortality and
we also tested the associations between SNPs in NFE2L2 and
triglyceride and cholesterol levels.
METHODS
Study population. We studied subjects of the Vlagtwedde-Vlaardin-
gen cohort, a general population-based cohort of exclusively Cauca-
sian individuals of Dutch descent, recruited from Vlagtwedde, a rural
area, and Vlaardingen, an urban area in the Netherlands (25). This
cohort started in 1965, and participants had medical exams every 3 yr
until the last survey in 1989/1990. In each survey the Dutch version
of the British Medical Council standardized questionnaire was filled
in, and spirometry was performed. In this study we included 1,390
subjects (16.4% of the original cohort) out of 2,467 subjects of whom
DNA was collected in the final survey in 1989/1990 (those with DNA
samples contained 1,500 ng isolated DNA). There were no differ-
ences in characteristics between the selected (n  1,390) and nonse-
lected group (25). The Vlagtwedde-Vlaardingen cohort was set up to
study respiratory health in the general population. During survey 2 and
3 (in 1970/72 and 1973/75) an add-on study was performed by
cardiologists. At that time the prevalence of cardiovascular problems
was much higher in males than in females, and therefore only males
were included in this cardiovascular add-on study. In the surveys of
1970/72 and 1973/75, fasting serum triglyceride and total cholesterol
levels were measured in 493 males out of the 1,390 genotyped
subjects. The vital status of all participants in the Vlagtwedde-
Vlaardingen study was assessed on December 31, 2008. We evaluated
three mortality outcomes, i.e., all-cause mortality (excluding external
causes of death) and cardiovascular and COPD mortality (either as
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primary or secondary cause of death). The causes of death were coded
according to the International Classification of Diseases (ICD-9 and
ICD-10, Table 1). Analyses on cause-specific mortality were per-
formed at Statistics Netherlands (The Hague). The study protocol was
approved by the local university medical hospital ethics committee,
University of Groningen, University Medical Center Groningen, The
Netherlands, and all participants gave their written informed consent.
Sample collection, DNA extraction, and genotyping. In 1989–1990,
neutrophil depots from peripheral blood samples were collected and
stored at 20°C. In 2003–2004 DNA was extracted from these
samples with a QIAamp DNA blood mini kit (Qiagen, Hilden,
Germany) and checked for purity and concentration with a NanoDrop
ND-1000 UV-Vis spectrophotometer (NanoDrop Technologies, Wil-
mington, DE) (25). We pairwise tagged NFE2L2 with five single
nucleotide polymorphisms (SNPs) according to the HapMap CEU
genotype data (release 23a) with r2 threshold of 0.8 and minor allele
frequency 5%. SNPs were genotyped at K-Bioscience (UK) using
their patent-protected competitive allele-specific PCR system
(KASPar) (16). Figure 1 shows the position of genotyped SNPs in the
NFE2L2 gene and linkage disequilibrium (LD) between genotyped
SNPs in the Vlagtwedde-Vlaardingen cohort. Hardy-Weinberg equi-
librium was tested by the 2-test (cut-off value P  0.05).
Statistical analysis. First, descriptive analyses were performed.
Differences in genotype distribution between deceased and living
subjects were tested by 2-tests. Cox proportional hazards regression
adjusted for sex, age, forced expiratory volume in 1 second (FEV1)
%predicted, and pack-years of smoking (all at the 1989/1990 survey)
was used to evaluate the association between SNPs and all-cause,
cardiovascular, and COPD mortality. Time was defined from the
examination in 1989/1990 until death, end of follow-up in 2008, or
last registration if subjects were lost to follow-up. Survival curves
were depicted based on these Cox models. In addition, stratified
analyses according to sex and smoking habits were performed.
Linear regression adjusted for age at the measurement was used to
evaluate the associations between lipid profile i.e., triglyceride and
total cholesterol levels and SNPs. The triglyceride and cholesterol
levels were logarithmically transformed to obtain a normal distribu-
tion. P values  0.05 were considered statistically significant (tested
2-sided). All statistical analyses were performed with IBM SPSS 20
software.
RESULTS
Table 2 shows the population characteristics at the survey in
1989/1990, according to vital status on December 31st, 2008.
After 18 yr of follow-up, 78.2% (n  1,087) of the cohort was
still alive. We had an almost perfect follow-up, since only 19
(1.4%) of the genotyped participants were lost to follow-up.
Among all 284 deaths, 107 (37.7%) occurred from cardiovas-
cular disease (CVD), and 20 (14.2%) from COPD. The 14
(4.9%) deaths due to external causes were excluded from the
analyses. All tested SNPs were in Hardy-Weinberg equilib-
rium. A comparison of the characteristics of the genotyped
subjects at baseline (survey in 1989/90) stratified by genotype
for each SNP (data not shown) shows that, except for a slightly
higher FEV1% predicted in subjects homozygous for the minor
allele of rs1806649, no differences between the genotypes
were seen.
All-cause, cardiovascular, and COPD mortality. Table 3 shows
the genotype distributions and the hazard ratios (HR) of living
Table 1. ICD codes for the investigated causes of death
Cause of Death ICD-9 ICD-10
External causes*  800 S, T, V, W, X, Y
CVD 390–398, 401–405, 410–417, 420–438, 440–448,
451–459, 785.4
G45–G46, I00–I15, I20–I28, I30–I52, I60–I69, I70–I79,
I80–I89, I95–I97, I98.2, I98.8, I99, M30–M31,
N28.0, R02, R58
COPD 490–492, 494, 496 J40–J44, J47
*Suicides, homicides, traffic accidents, etc. ICD, International Classification of Diseases; CVD cardiovascular disease; COPD, chronic obstructive pulmonary
disease.
Fig. 1. Position of genotyped single nucleotide polymorphisms (SNPs) in the
nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) gene and linkage dis-
equilibrium plot (100·r2) in the Vlagtwedde-Vlaardingen cohort. The black
boxes represent exons.
Table 2. Characteristics of participants at visit 1989/1990
by vital status on Dec. 31st, 2008
Status on 31 Dec. 2008 Alive Deceased P Value
n (%) 1,087 (78.2) 284 (20.4)
Men 525 (48.3) 178 (62.7) 0.001
Vlagtwedde 981 (90.2) 258 (90.8) 0.761
Age at last status, yr 68.4 (54.2–90.8) 72.6 (41.4–87.4) 0.001
Ever smokers 711 (65.4) 219 (77.1) 0.001
Pack-years in ever smokers 17.2 (0.1–117.1) 27.1 (0.6–262.2) 0.001




External causes 14 (4.9)
Other causes 149 (52.5)
All variables are expressed as number (%) or mean (SD) or median (range)
as appropriate. FEV1, forced expiratory volume in 1 second. *Either as primary
or secondary cause of death: 6 subjects had both CVD and COPD as primary
and secondary cause of death.
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subjects and those who had died during 18 yr of follow-up.
Among subjects who died, the carriers of the minor allele of
SNP rs13001694 were significantly less common (58%) than in
living subjects (66%). Furthermore, individuals carrying the
minor allele of rs13001694 had a significantly reduced HR for
all-cause mortality compared with wild types [HR 0.77; 95%
confidence interval (CI), 0.59 to 1.00; P  0.049] (Table 3).
Stratified analysis according to sex showed no significant HR
in females and males [0.83 (0.54–1.28) and 0.77 (0.55–1.07),
respectively] (Table 4). The stratified analysis according to
smoking habits showed that the protective effect of rs13001694
was observed in ever smokers only: HR  0.71 [95% CI
(0.53–0.95), P  0.023] (Table 5). Carriers of the minor allele
of rs2364723 had a significantly reduced risk of cardiovascular
mortality: HR  0.49, (0.33–0.74). In stratified analyses the
risk of cardiovascular mortality associated with SNP
rs2364723 was shown to be robust: females 0.35 (0.17–0.70),
males 0.56 (0.33–0.93), never smokers 0.46 (0.20–1.07), ever
smokers 0.50 (0.31–0.79), (Tables 4 and 5). Carriers of the
minor allele of rs1806649 had a reduced risk of COPD mortality:
HR  0.26 (0.08–0.89). Survival curves according to genotypes
of rs13001694, rs2364723, and rs1806649 clearly show the dif-
ferences in mortality risk (Figs. 2, 3, and 4, respectively). Dom-
inant genetic models (homozygous wild-type individuals vs.
heterozygous/homozygous minor allele individuals) were used
for all analyses, since the number of individuals homozygous
for the minor allele was low, especially within subjects who
died from CVD or COPD. Results of codominant models (data
not shown) indicate that, in general, the HRs for heterozygotes
and homozygotes for the minor allele are similar.
Triglycerides and cholesterol level. Heterozygotes and ho-
mozygotes for the minor allele of rs2364723 had 0.084 lower
ln(triglyceride levels) compared with the wild types, whereas
heterozygotes and homozygotes for the minor allele of
rs13001694, rs1806649, and rs6726395 had respectively 0.110,
0.113, and 0.107 higher ln(triglyceride levels) compared with
their wild types.
None of the SNPs was significantly associated with choles-
terol levels (Table 6). Results of codominant models (data not
shown) indicate that, in general, the effect estimates for
heterozygotes and homozygotes for the minor allele are com-
parable.
Cigarette smoking has an adverse effect on blood lipids, and,
indeed in the Vlagtwedde-Vlaardingen cohort, smoking (pack-
years) was associated with triglyceride and cholesterol levels.
However, smoking does not seem to be a confounder of the
associations between lipids and SNPs, since in the analysis
additionally adjusted for smoking (pack-years) the effects of
the SNPs on triglycerides and cholesterol levels remained
similar (data not shown).
DISCUSSION
We found a 20% reduced mortality risk among minor allele
carriers of SNP rs13001694 in NFE2L2 during the 18 yr of
follow-up in the general population. Recently, a study that
compared expression of oxidoreduction genes in the naked
mole rat, the longest-living rodent known, to expression in
mice, has shown that NFE2L2 was sixfold higher expressed in
the rats (26). Here we show evidence to support the hypothesis
Table 3. Distribution of genotypes and HR for all-cause, CVD, and COPD mortality











rs4243387 TT 898 (85.0) 238 (85.3) 84 (80.0) 19 (95.0)
TCCC 158 (15.0) 41 (14.7) 21 (20.0) 1 (5.0) 0.96 (0.67–1.37) 1.52 (0.93–2.47) 0.42 (0.06–3.23)
rs2364723 GG 481 (46.1) 117 (41.9) 60 (56.6) 6 (30.0)
GCCC 562 (53.9) 162 (58.1) 46 (43.4)* 14 (70.0) 0.96 (0.74–1.25) 0.49 (0.33–0.74)* 1.46 (0.45–4.72)
rs13001694 AA 354 (33.7) 117 (42.4)* 40 (38.5) 9 (45.0)
AGGG 697 (66.3) 159 (57.6) 64 (61.5) 11 (55.0) 0.77 (0.59–1.00)* 0.89 (0.58–1.34) 0.47 (0.18–1.24)
rs1806649 CC 549 (53.8) 153 (57.5) 55 (54.5) 12 (66.7)
CTTT 471 (46.2) 113 (42.5) 46 (45.5) 6 (33.3) 0.94 (0.72–1.22) 0.96 (0.63–1.46) 0.26 (0.08–0.89)*
rs6726395 GG 305 (28.9) 95 (34.4) 29 (27.4) 9 (45.0)
GAAA 751 (71.1) 181 (65.6) 77 (72.6) 11 (55.0) 0.89 (0.67–1.17) 1.23 (0.78–1.94) 0.48 (0.18–1.28)
HR, hazard ratio; CI, confidence interval. *P  0.05.


















rs4243387 TT 467 (86.5) 93 (88.6) 33 (82.5) 431 (83.5) 145 (83.3) 51 (78.5)
TCCC 73 (13.5) 12 (11.4) 7 (17.5) 0.96 (0.51–1.81) 1.71 (0.75–3.91) 85 (16.5) 29 (16.7) 14 (21.5) 0.98 (0.63–1.51) 1.47 (0.81–2.70)
rs2364723 GG 257 (47.9) 44 (41.9) 26 (65.0) 224 (44.2) 73 (42.0) 34 (51.5)
GCCC 279 (52.1) 61 (58.1) 14 (35.0)* 0.91 (0.59-1.39) 0.35 (0.17-0.70) 283 (55.8) 101 (58.0) 32 (48.5) 0.95 (0.68–1.33) 0.56 (0.33–0.93)
rs13001694 AA 180 (33.1) 40 (39.2) 12 (31.6) 174 (34.3) 77 (44.3) 28 (42.4)
AGGG 364 (66.9) 62 (60.8) 26 (68.4) 0.83 (0.54-1.28) 1.25 (0.60-2.61) 333 (65.7) 97 (55.7)* 38 (57.6) 0.77 (0.55-1.07) 0.78 (0.47-1.31)
rs1806649 CC 290 (54.7) 54 (54.0) 20 (52.6) 259 (52.9) 99 (59.6) 35 (55.6)
CTTT 240 (45.3) 46 (46.0) 18 (47.4) 1.25 (0.82–1.92) 1.23 (0.62–2.44) 231 (47.1) 67 (40.4) 28 (44.4) 0.82 (0.58–1.15) 0.89 (0.53–1.50)
rs6726395 GG 162 (29.5) 35 (34.0) 10 (25.0) 143 (28.2) 60 (34.7) 19 (28.8)
GAAA 387 (70.5) 68 (66.0) 30 (75.0) 0.86 (0.55–1.33) 1.44 (0.67–3.09) 364 (71.8) 113 (65.3) 47 (71.2) 0.93 (0.65–1.32) 1.17 (0.66–2.07)
SNP, single nucleotide polymorphism. *P  0.05.
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that NFE2L2 may be one of the genes contributing to individ-
ual differences in human lifespan. In further analysis of sur-
vival in the Vlagtwedde-Vlaardingen cohort, we showed that
the effect is independent of sex, since the effect was similar in
females and males. In stratification according to smoking
habits we found the significant protective effect of rs13001694
in ever smokers only, so it seems that the effect of the A/G
substitution in rs13001694 may be exerted only under oxida-
tive stress conditions. Indeed, a previous study showed that
cigarette smoke exposure, a potent source of oxidative stress in
the human lungs (3), may influence NFE2L2 activity in alve-
olar macrophages by inducing NFE2L2 nuclear accumulation
and upregulation of NFE2L2 target genes (19). Furthermore,
SNP rs10183914, which is highly correlated with rs13001694
(r2  0.97, 1000 Genomes project), showed a protective effect
on lung function decline in smokers in the Lung Health Study
(LHS) (15). However, this result was not replicated when
rs13001694 was tested in smokers from the Vlagtwedde-
Vlaardingen cohort (15). Sandford et al. (15) explain that the
lack of replication may be due to differences in recruitment
between the two studies, as the LHS selected mild to moderate
COPD patients and the Vlagtwedde-Vlaardingen cohort was
from the general population, and the genetic factors associated
with lung function decline in COPD patients and in the general
population could be different. In our study, we adjusted the
analysis for FEV1% predicted, thus the association of rs13001694
with better survival is independent of lung function level.
Another important finding in our study is that SNP
rs2364723 is associated with a reduced risk of cardiovascular
mortality. Even more interesting, the protective effect of this
SNP was consistent within groups that have different mortality
risks, i.e., females and males and never and ever smokers. This
finding is of high importance since CVD is a main cause of
morbidity and a leading cause of death in the elderly. A
previous study in the Vlagtwedde-Vlaardingen cohort on the
NFE2L2 gene investigated its relationship to lung function
level and decline (16). Interestingly, SNP rs2364723 was
associated with a lower FEV1 level, and the same direction of
Table 5. Distribution of genotypes and HR for all-cause and cardiovascular mortality stratified according to smoking habits
SNP Genotype
















rs4243387 TT 313 (87.2) 55 (87.3) 21 (84.0) 585 (83.9) 183 (84.7) 63 (78.8)
TCCC 46 (12.8) 8 (12.7) 4 (16.0) 0.93 (0.40–2.19) 1.59 (0.53–4.71) 112 (16.1) 33 (15.3) 17 (21.2) 0.99 (0.66–1.47) 1.53 (0.89–2.66)
rs2364723 GG 161 (45.2) 29 (45.3) 16 (61.5) 320 (46.6) 88 (40.9) 44 (55.0)
GCCC 195 (54.8) 35 (54.7) 10 (38.5) 0.88 (0.51–1.53) 0.46 (0.20–1.07) 367 (53.4) 127 (59.1) 36 (45.0) 0.96 (0.71–1.29) 0.50 (0.31–0.79)*
rs13001694 AA 128 (35.9) 18 (28.6) 6 (25.0) 226 (32.6) 99 (46.5) 34 (42.5)
AGGG 229 (64.1) 45 (71.4) 18 (75.0) 1.10 (0.61–2.00) 1.57 (0.57–4.33) 468 (67.4) 114 (53.5)* 46 (57.5) 0.71 (0.53–0.95)* 0.80 (0.50–1.27)
rs1806649 CC 199 (56.2) 32 (51.6) 12 (48.0) 350 (52.6) 121 (59.3) 43 (56.6)
CTTT 155 (43.8) 30 (48.4) 13 (52.0) 1.47 (0.84–2.55) 1.44 (0.62–3.33) 316 (47.4) 83 (40.7) 33 (43.4) 0.84 (0.62–1.14) 0.86 (0.53–1.39)
rs6726395 GG 112 (30.9) 16 (25.8) 6 (23.1) 193 (27.8) 79 (36.9) 23 (28.8)
GAAA 250 (69.1) 46 (74.2) 20 (76.9) 1.12 (0.60–2.09) 1.49 (0.55–4.04) 501 (72.2) 135 (63.1)* 57 (71.2) 0.85 (0.62–1.15) 1.19 (0.71–2.00)
*P  0.05.
Fig. 2. Survival curves for all-cause mortality according to SNP rs13001694.
Cum, cumulative; HR, hazard ratio.
Fig. 3. Survival curves for cardiovascular mortality according to SNP
rs2364723.
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the effect was observed in the British 1958 Birth Cohort (7,
16). Based on our finding showing the protective effect of this
SNP on cardiovascular mortality, different pathways via which
NFE2L2 acts in pulmonary and cardiovascular events might be
involved. There is evidence that NFE2L2 plays a key role in
preserving a healthy endothelial phenotype and maintaining the
functional integrity of vasculature (24). Furthermore, NFE2L2
dysfunction may lead to functional impairment of arteries,
increasing susceptibility of blood vessels to injury in metabolic
diseases (23). NFE2L2 is essential for normal endothelial
angiogenic processes, and its dysfunction may be a potential
mechanism underlying impaired angiogenesis and decreased
microvascular density in aging (24). Several studies suggest
that NFE2L2 alters susceptibility to atherosclerosis (1, 5, 18,
27). One of these studies indicated that activation of NFE2L2
may exert antiatherogenic effects in vascular endothelium by
suppressing inflammation (27), whereas another showed
NFE2L2 expression unexpectedly promotes atherosclerotic le-
sions formation (1). NFE2L2 may affect atherosclerosis devel-
opment since it regulates hepatic lipid homeostasis via activa-
tion of lipogenic genes expression (1, 8, 21). We found that
rs2364723 was associated with lower triglyceride levels in
male subjects. Triglyceride level is highly related to cardiovas-
cular mortality; therefore, it is plausible that rs2364723 con-
tributes to the observed, reduced cardiovascular mortality via
its favorable effect on triglyceride levels. The publicly avail-
able data of the British 1958 Birth Cohort (7) showed that
rs2364723 is also associated with lower cholesterol levels, and
it gives us another intermediate phenotype by which rs2364723
exerts its overall protective effect on cardiovascular mortality.
This SNP is in LD (r2  0.99) with promoter polymorphism
rs35652124 (653A/G) in the Vlagtwedde-Vlaardingen co-
hort (16). Marzec et al. (13) have reported that rs35652124
impedes the transcriptional activity of NFE2L2 in vitro. Hence,
it is possible that rs2364723 is not the causative variant, but
that its association with cardiovascular mortality, due to almost
complete LD, represents the effect of rs35652124. NFE2L2
knockout mice exhibit 	50% reduction in the degree of aortic
atherosclerosis compared with the wild-type littermates (1);
thus in this light a SNP that attenuates NFE2L2 expression or
activity is indeed likely to have the protective potential for
cardiovascular morbidity and mortality in humans. Further-
more, it is known that decreased expression of NFE2L2 in vitro
is associated with acute lung injury, characterized by pulmo-
nary edema and inflammation (13). Therefore, it seems that
NFE2L2 may have different local vascular and pulmonary
effects, which could explain the opposite effects of rs2364723
on cardiovascular mortality and triglyceride levels on the one
hand and on lung function level (FEV1) on the other hand.
The other investigated SNPs (rs13001694, rs1806649, and
rs6726395) were associated with increased triglyceride levels,
and interestingly these SNPs were also associated with in-
creased cholesterol levels in the British 1958 Birth Cohort (7),
which confirms that these SNPs indeed affect metabolism of
lipoproteins in humans.
We found a reduced risk of COPD mortality in carriers of
the T allele of rs1806649, and we thus confirm the relevance of
this SNP in COPD. Canova et al. (2) have already introduced
the wild-type allele (C) of rs1806649 as a factor increasing the
risk of air pollution-induced asthma/COPD hospital admis-
sions. In this light, indeed, the T allele of rs1806649 may have
protective potential compared with the C allele. It would be
interesting to investigate further whether this effect differs
depending on smoking habits, but during 18 yr of follow-up
Fig. 4. Survival curves for chronic obstructive pulmonary disease (COPD)
mortality according to SNP rs1806649.
Table 6. Estimated effects of the NFE2L2 genetic variation on Ln-transformed triglyceride and cholesterol levels
SNP Genotype
Triglyceride Levels Cholesterol Levels
n B SE P Value n B SE P Value
rs4243387 TT 400 345
TCCC 83 0.015 0.056 0.783 76 0.020 0.023 0.397
rs2364723 GG 218 184
GCCC 259 0.084 0.043 0.050 231 0.006 0.018 0.756
rs13001694 AA 176 164
AGGG 299 0.110 0.044 0.013 249 0.026 0.019 0.172
rs1806649 CC 254 227
CTTT 205 0.113 0.043 0.009 174 0.003 0.019 0.875
rs6726395 GG 142 130
GAAA 336 0.107 0.047 0.022 288 0.014 0.020 0.486
*Regression coefficient (B), its standard error (SE), and P value obtained with linear regression analysis adjusted for age at the measurement.
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only 20 deaths due to COPD occurred, and stratification
according to smoking habits was not feasible because of a lack
of study power. However, all the subjects who died of COPD
were ever smokers, and we showed that the protective effect is
observed in this group.
The functionally important SNP rs6721961 (617C/A) lo-
cated in the NFE2L2 promoter region significantly impedes
NFE2L2 function and is associated with increased risk of lung
cancer (20) and acute lung injury (13). In our study we tested
rs4243387, which is in perfect LD (r2  1.0) with rs6721961,
but we did not observe an association with mortality risk. With
regard to the longevity phenotype, according to the GWAS
Central database (http://www.gwascentral.org) none of the
previous genome-wide association studies reported any SNP in
NFE2L2 to be associated with longevity in humans.
Polymorphisms in NFE2L2 may alter expression of NFE2L2
or its ability to translocate from cytoplasm to the nuclear
binding sites (13). Based on the data presented by Marzec et al.
(13) two functional SNPs (rs6721961 and rs6706649) impede
the activity of the promoter region by 50% (indicated by
lower luciferase activity in vitro) and one (rs35652124) by
	50%. Thus in humans, we would not expect changes close to
sixfold higher expression or activity, as it was shown in the
naked mole rat (26). However, it is hard to predict to what
extent the expression of NFE2L2 might be altered by SNPs. It
may also differ between different organs, such as lungs, liver,
brain, or heart and their exposure to oxidative stress.
Strengths and Limitations
The major strength of the current study is the longitudinal
design. The follow-up period of 18 yr provided a wide time
window for evaluating survival of subjects, who were sampled
from the general population. Also the high follow-up rate
should be mentioned, since 98.6% of the included subjects
could be traced back.
We could evaluate the associations between triglyceride and
cholesterol levels in males only, since these measurements
were not performed in females in the Vlagtwedde-Vlaardingen
cohort. Nonetheless, in the previous studies, most of the effects
of NFE2L2 on lipids levels were observed in male mice (1),
and we were able to investigate the relationship, previously
shown in mice, in humans.
The small number of deaths due to COPD (i.e., 20) could be
considered a limitation of our study. However, SNP rs1806649,
which showed association with reduced COPD mortality, was
previously associated with asthma/COPD hospital admissions in
the same direction (2), making our finding consistent with the
results of previous studies.
In summary, this is the first study showing that NFE2L2
plays an important role in human survival, as shown by its
associations with reduced all-cause, cardiovascular, and COPD
mortality in the general population.
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